Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.
Obsessive-compulsive disorder (OCD) is a common psychiatric disorder that produces significant morbidity. The introduction of serotonin reuptake inhibitors in the 1980s represented an important advance in the treatment of OCD. However, few patients show complete remission of their symptoms, and some patients show minimal improvement with existing treatments. We review current treatment strategies and initial data supporting the efficacy of glutamate modulating agents as a novel class of pharmaceuticals for the treatment of OCD. Functional neuroimaging studies repeatedly reported metabolic hyperactivity in the cortico-striato-thalamo-cortical circuitry in patients with OCD. Recent magnetic resonance spectroscopy studies provide evidence of elevated glutamate levels in several brain regions in patients suffering from OCD. These findings raised the possibility that agents that reduce glutamate hyperactivity or its consequences in the CNS might be efficacious as novel therapeutic interventions. Indeed, initial evidence from our group suggests that the antiglutamatergic agent riluzole (Rilutek), which was developed for the treatment of amyotrophic lateral sclerosis, is effective in treatment-resistant OCD. Case reports suggest that other agents that modulate glutamatergic activity may likewise be effective. This new application of glutamate modulating agents holds promise for the treatment of this disabling and often inadequately treated disease.
Yale University Department of Psychiatry, New Haven, Connecticut 06508, USA.
Christopher
C
Pittenger
John H
JH
Krystal
Vladimir
V
Coric
D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001921:Brain / Q000033:anatomy & histology / Q000473:pathology; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D018698:Glutamic Acid / Q000134:cerebrospinal fluid / Q000502:physiology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009771:Obsessive-Compulsive Disorder / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology*
D000929:Antidepressive Agents, Tricyclic; D018691:Excitatory Amino Acid Antagonists; D018698:Glutamic Acid